Presentation is loading. Please wait.

Presentation is loading. Please wait.

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Published byΑδώνια Αλιβιζάτος Modified over 5 years ago

Similar presentations

Presentation on theme: "Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62"— Presentation transcript:

1 Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

2 Baseline characteristics of study participants according to education and two subgroups
Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

3 Number of statin users 2004–2006 among participants in population-based studies 2000–2002, who reported never use of statins at baseline Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

4 Adjusted relative risk (RR) of starting statin treatment among participants in population-based studies , who reported never use of statins at baseline Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

5 Probability of statin treatment in according to total cholesterol at baseline in and educational level Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

6 Number of statin prescriptions dispensed in the period among study participants (n=1842), by level of education and subgroup Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Download ppt "Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62"

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165: 2264-2271.

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:1264-72.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Frank B. Hu et al N Engl J Med 2004; 351: 2694- 703 Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:2742-53.

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:
Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:2128-2135.

Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:
Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:1556-1563.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:2184- 92.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:
Solomon Tesfaye et al N Engl J Med 2005;352:341- 50 Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.
Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75. Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:
Shalev V, et al. Arch Intern Med 2009; 169:260-268.

Shalev V, et al. Arch Intern Med 2009; 169:
Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Similar presentations

Ads by Google